Topic: Myelin Oligodendrocyte Glycoprotein

Neuromyelitis-optica spectrum disorders (NMOSD) usually associate with aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) antibodies. Seronegative-NMOSD (SN-NMOSD) has been described, but the clinical-therapeutic profile is poorly defined.We searched PubMed, Scopus and Google Scholar databases for studies reporting SN-NMOSD patients, on which anti-MOG-Abs and AQP4-Abs were tested. PRISMA guidelines and methodological quality control were assessed. Fixed or random-effects models were used to pool results across studies.We included 36/1027 articles screened and analyzed 591 SN-NMOSD

Myelin producing human oligodendrocytes express the main thyroid hormone plasma membrane transporter, monocarboxylate transporter 8 (MCT8). Our group has demonstrated that MCT8 is dysfunctional in conditions of developmental or acquired myelin diseases such as progressive multiple (MS). Small molecules that can bypass MCT8, such as the thyroid hormone analog, diiodothyropropionic acid (DITPA), may improve re-myelination and provide neuroprotection in the central nervous system (CNS), following immune-mediated damage described in a mouse model that mimics MS-like disease.Using the myelin oligod